Stock ONVO ORGANOVO HOLDINGS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Organovo Holdings, Inc.

Equities

ONVO

US68620A2033

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
0.9881 USD -1.19% Intraday chart for Organovo Holdings, Inc. -14.08% -10.98%
Apr. 15 Organovo's fatty liver disease drug meets main goal in mid-stage study RE
Apr. 15 Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
AQ
Organovo's fatty liver disease drug meets main goal in mid-stage study
RE
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
AQ
Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
CI
Organovo: Fiscal Q3 Earnings Snapshot
AQ
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
AQ
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings
CI
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
AQ
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results
AQ
Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results
CI
Organovo: Fiscal Q2 Earnings Snapshot
AQ
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
CI
Organovo Highlights FXR314 Combination Therapy Potential and Plan
AQ
Organovo Holdings, Inc. Highlights FXR314 Combination Therapy Potential and Plan
CI
Organovo : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
Organovo to Participate in the H.C. Wainwright Global Investment Conference
AQ
Organovo : Change in Certifying Accountants - Form 8-K
PU
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
AQ
Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ONVO Stock
  4. News Organovo Holdings, Inc.